February 24, 2022
Highlighting proprietary pipeline of oncology drug candidates that spare healthy normal cells by modulating signaling dynamics to focus therapeutic efficacy against tumor cells CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company
January 24, 2022
Highlighting proprietary pipeline of oncology drug candidates that spare healthy normal cells by modulating signaling dynamics to focus therapeutic efficacy against tumor cells CAMBRIDGE, Mass., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company
Displaying 11 - 20 of 23
Print Page
Email Alerts
Email Page
RSS Feeds